PL2825161T3 - Inhibitory ludzkiej ezh2 i sposoby ich zastosowania - Google Patents

Inhibitory ludzkiej ezh2 i sposoby ich zastosowania

Info

Publication number
PL2825161T3
PL2825161T3 PL13711265T PL13711265T PL2825161T3 PL 2825161 T3 PL2825161 T3 PL 2825161T3 PL 13711265 T PL13711265 T PL 13711265T PL 13711265 T PL13711265 T PL 13711265T PL 2825161 T3 PL2825161 T3 PL 2825161T3
Authority
PL
Poland
Prior art keywords
inhibitors
methods
human ezh2
ezh2
human
Prior art date
Application number
PL13711265T
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Sarah Kathleen Knutson
Timothy James Nelson Wigle
Original Assignee
Epizyme, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/418,242 external-priority patent/US9175331B2/en
Application filed by Epizyme, Inc. filed Critical Epizyme, Inc.
Publication of PL2825161T3 publication Critical patent/PL2825161T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
PL13711265T 2012-03-12 2013-03-12 Inhibitory ludzkiej ezh2 i sposoby ich zastosowania PL2825161T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/418,242 US9175331B2 (en) 2010-09-10 2012-03-12 Inhibitors of human EZH2, and methods of use thereof
EP13711265.2A EP2825161B1 (en) 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof
PCT/US2013/030565 WO2013138361A1 (en) 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2825161T3 true PL2825161T3 (pl) 2019-06-28

Family

ID=47913638

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13711265T PL2825161T3 (pl) 2012-03-12 2013-03-12 Inhibitory ludzkiej ezh2 i sposoby ich zastosowania

Country Status (14)

Country Link
EP (2) EP3536314A1 (pl)
JP (2) JP6321619B2 (pl)
KR (4) KR102453519B1 (pl)
CN (2) CN104540500B (pl)
AU (4) AU2013232229B2 (pl)
CA (2) CA3177515A1 (pl)
DK (1) DK2825161T3 (pl)
ES (1) ES2718900T3 (pl)
HU (1) HUE042271T2 (pl)
PL (1) PL2825161T3 (pl)
PT (1) PT2825161T (pl)
RU (2) RU2019132222A (pl)
TR (1) TR201904660T4 (pl)
WO (1) WO2013138361A1 (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2836216B1 (en) * 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
JP6254169B2 (ja) * 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
BR112015008480A2 (pt) * 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
US20160361309A1 (en) * 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
EA038337B1 (ru) * 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
CN106795561B (zh) 2014-06-19 2021-04-16 纪念斯隆-凯特琳癌症中心 用于对ezh2抑制剂的应答的生物标志物
CN106794177A (zh) * 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
CA2964629A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
KR102964530B1 (ko) * 2014-11-17 2026-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
WO2016172332A1 (en) * 2015-04-22 2016-10-27 The University Of North Carolina At Chapel Hill A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility
EA201890009A1 (ru) 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US20180296563A1 (en) * 2015-09-25 2018-10-18 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor
EP3371601A1 (en) 2015-11-05 2018-09-12 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
WO2017184999A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
US10933068B2 (en) * 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
CA3044691A1 (en) 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
EP3441388A1 (en) * 2016-11-11 2019-02-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 4,5,6-tri-substituted indazoles derivatives, preparation thereof, and use thereof in medicines
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
WO2019204998A1 (zh) * 2018-04-25 2019-10-31 北京肿瘤医院 Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用
EP3801497B1 (en) * 2018-06-03 2023-03-22 Wen-Pin Chen Method for treating non-compaction cardiomyopathy
JP7411256B2 (ja) * 2018-07-27 2024-01-11 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 多置換ベンゼン環化合物、製造方法及びその用途
ES3034869T3 (en) 2019-04-22 2025-08-25 Univ Pittsburgh Commonwealth Sys Higher Education Tg02 for use in treating gliomas in pediatric subjects
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN113024516B (zh) * 2021-03-29 2022-05-17 中国药科大学 双靶点parp/ezh2抑制剂、制备方法及用途
EP4392034A1 (en) 2021-08-25 2024-07-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
CN119143880A (zh) * 2024-09-20 2024-12-17 上海交通大学医学院附属第九人民医院 抗ezh2蛋白抗体及其应用
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
JP5160885B2 (ja) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法
ES2324435B1 (es) * 2005-10-27 2010-05-31 Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas.
WO2008101118A2 (en) * 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2009124137A2 (en) * 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
BR112013005806B1 (pt) * 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9730925B2 (en) * 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer

Also Published As

Publication number Publication date
CN104540500B (zh) 2019-02-22
AU2013232229B2 (en) 2017-11-23
JP6321619B2 (ja) 2018-05-09
CN110420327A (zh) 2019-11-08
EP2825161B1 (en) 2019-01-02
CA2867282A1 (en) 2013-09-19
RU2704445C2 (ru) 2019-10-28
ES2718900T3 (es) 2019-07-05
AU2013232229A1 (en) 2014-10-02
DK2825161T3 (en) 2019-04-08
TR201904660T4 (tr) 2019-05-21
KR102453519B1 (ko) 2022-10-11
KR20220139453A (ko) 2022-10-14
JP2018083821A (ja) 2018-05-31
PT2825161T (pt) 2019-04-29
RU2014141045A (ru) 2016-05-10
JP2015511603A (ja) 2015-04-20
AU2021202119A1 (en) 2021-05-06
EP2825161A1 (en) 2015-01-21
EP3536314A1 (en) 2019-09-11
RU2019132222A (ru) 2021-06-03
KR20210079384A (ko) 2021-06-29
WO2013138361A1 (en) 2013-09-19
AU2018201176A1 (en) 2018-03-08
KR20230145531A (ko) 2023-10-17
KR20140147836A (ko) 2014-12-30
CA2867282C (en) 2024-04-02
KR102267502B1 (ko) 2021-06-24
KR102587175B1 (ko) 2023-10-06
HK1205938A1 (en) 2015-12-31
CN110420327B (zh) 2022-05-03
HUE042271T2 (hu) 2019-06-28
CA3177515A1 (en) 2013-09-19
CN104540500A (zh) 2015-04-22
AU2019250181A1 (en) 2019-11-07
JP6592071B2 (ja) 2019-10-16

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for tissue treatment
HUE042271T2 (hu) Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
SG11201504022RA (en) Glutamase inhibitors and method of use
SG11201406948PA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EP2709562A4 (en) FABRIC BACKUP DEVICES AND USE METHOD THEREFOR
SI2909204T1 (sl) Inhibitorji GSK3 in postopki njihove uporabe
IL227440A0 (en) Spherical support device and methods of use
SG10201609940RA (en) Compounds and their methods of use
ZA201306188B (en) Mst1 kinase inhibitors and methods of their use
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL233581B (en) Body expandable device and method for use
SG2014011654A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG10201608969PA (en) Oilfield apparatus and methods of use
IL231270A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceuticals containing them and methods of use
EP2742033A4 (en) FLAVONOID COMPOUNDS AND METHODS OF USE
HUE046572T2 (hu) TFPI inhibitorok és alkalmazási eljárások
IL234841A0 (en) Administration forms of halofuginone and methods of use
SG11201406895QA (en) Oilfield apparatus and methods of use
IL240505A0 (en) Accumulations of lanthanides and methods for their use
ZA201404689B (en) Umbilical splint and method of use
EP2768331A4 (en) PROTECTIVE DEVICES, COMPONENTS THEREFOR AND METHODS OF USE THEREOF
EP2839023A4 (en) EASY TO USE PRIMER AND USE METHOD THEREFOR
AU2013101402A4 (en) Timber treatment formulations and methods of use
GB201203663D0 (en) Note pad and method of use thereof
GB201216724D0 (en) Note pad and method of use thereof